LPCAT1 had never been reported in cervical cancer but was reported to promote gefitinib resistance through upregulation of the EGFR/PI3K/Akt signaling pathway in lung carcinoma [19], and it has been recognized as a promising prognostic biomarker in liver cancer [20]. This evidence concerns the gene EGFR and liver cancer.